¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2022 ´ëÇÑÄ¡¸ÅÇÐȸ Ãá°è Çмú´ëȸ : 2022-04-16

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2022 ´ëÇÑÄ¡¸ÅÇÐȸ Ãá°è Çмú´ëȸ : 2022-04-16
±³À°ÀÏÀÚ : 2022-04-16
±³À°Àå¼Ò : ÇÏÀ̺긮µå (Àå¼Ò: ¹é¹ü±è±¸±â³ä°ü)  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ-¿ÀÇÁ¶óÀÎ º´Çà) 2022 ´ëÇÑÄ¡¸ÅÇÐȸ Ãá°è Çмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇÑÄ¡¸ÅÇÐȸ 
´ã´çÀÚ : ±èÁÖ¿Á
¿¬¶ôó : 02-587-7462  
À̸ÞÀÏ : secretkda@thedementia.co.kr      
±³À°Á¾·ù : ½Å°æ°ú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 8 ½Ã°£ 15ºÐ  
¼¼ºÎ¼ö°­·á : 50,000¿ø      
ºñ°í ÀϹÝȸ¿ø 2¸¸¿ø, Á¤È¸¿ø 3¸¸¿ø, ºñȸ¿ø 5¸¸¿ø (ÇöÀåµî·Ï ¾øÀ½)      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 08:50~09:00 Opening remarks  () 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 09:00~09:20 Genetics Update  ¹Ú¿µÈ£(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 09:20~09:40 Microbiome Update  ÀÌ°ÇÈ£(Á¶¼±´ëÇб³) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 09:40~10:05 The Gantenerumab Global Development Program for Alzheimer''''s Disease  Scott Schobel(Roche) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 10:05~10:30 Clinical, Biomarker, and Safety Update BAN2401-G000-201, the Lecanemab Phase 2 Proof of Concept Study and Open Label Extension  Chad Swanson(Eisai) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 10:30~10:55 Future for the development of Alzheimer¡¯s disease modifiers clinical trial results of donanemab  Ena Oru(Lilly) 
È޽Ġ04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 10:55~11:20 Coffee Break  () 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 11:20~12:00 Can we prevent aging?  ÇѼ³Èñ(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 12:00~12:40 Current and future direction of AD biomarkers  Gill Rabinovici(UCSF) 
±âŸ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 12:40~13:00 ÃÑȸ  () 
½Ä»ç 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 13:00~14:20 Lunch ¹× Poster session  () 
Åä·Ð 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 14:20~15:20 Pannel discussion for Current Issues : Aducanumab! Is this new hope for Alzhiemer's?  ¹Ú±âÇü(°¡ÃµÀÇ´ë) 
È޽Ġ04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 15:20~15:30 Coffee Break  () 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room A) 15:30~15:50 Development of tau-targeted therapeutic strategy for dementia  ±èÀ±°æ(KIST) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room A) 15:50~16:10 Nanobiosensor technology for serological biomarker detection of neurodegenerative disease  È²±³¼±(°æÈñÀÇ´ë) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room A) 16:10~16:30 Genetic factors of Alzheimer's disease in the Korean population  ±èÈñÁø(¼º±Õ°üÀÇ´ë) 
È޽Ġ04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room A) 16:30~16:40 Coffee Break  () 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room A) 16:40~17:00 Clinical usefulness and need of blood biomarkers in the diagnosis and follow-up of AD  °í¼ºÈ£(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room A) 17:00~17:20 Introduction of Currently Available Blood Based Biomarker of AD  ÀåÀç¿ø(°­¿øÀÇ´ë) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room A) 17:20~17:40 Clinical application of AD blood biomarker: expectations & concerns  ½É¿ë¼ö(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room B) 15:30~15:50 Clinical application of A.I. in Dementia  ¼­»ó¿ø(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room B) 15:50~16:10 A.I in Neuroimaging of AD  Á¤¿ë(KAIST) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room B) 16:10~16:30 Dementia big data platforms in the UK, Europe and Korea  ±èÄ¡Çå(ÇѸ²ÀÇ´ë) 
È޽Ġ04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room B) 16:30~16:40 Coffee Break  () 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room B) 16:40~17:00 µðÁöÅÐ Ä¡·áÁ¦ÀÇ Çö¾È°ú ¹Ì·¡  ÇÑ¿µ¹Î ÁÖ¹«°ü(½ÄÇ°ÀǾàÇ°¾ÈÀüó) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room B) 17:00~17:20 µðÁöÅÐ Ä¡·áÁ¦ °³¹ß°ú ÇâÈÄ Àü¸Á  ±èÁø¿ì ´ëÇ¥(¢ßÇÏÀÌ) 
±³À°½Ã°£ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ (Room B) 17:20~17:40 µðÁöÅÐÇコÄɾî/µðÁöÅÐÄ¡·áÁ¦´Â ¾î¶»°Ô ºñÁö´Ï½º°¡ µÇ´Â°¡  ±èÄ¡¿ø »ó¹«(Ä«Ä«¿Àº¥Ã³½º) 
±âŸ 04-16 ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 17:40~17:50 Closing remarks ¹× ½Ã»ó½Ä  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2022 ´ëÇÑÄ¡¸ÅÇÐȸ Ãá°è Çмú´ëȸ : 2022-04-16""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) 2022³âµµ Çѱ¹Á¤½ÅºÐ¼®ÇÐȸ Á¤½ÅÄ¡·á Àü¹®°úÁ¤ : ÀΰÝÀå¾Ö Á¤½ÅÄ¡·á ¿öÅ©¼¥ 3 : 2022-04-16
´ÙÀ½±Û °æºÏ´ëÇб³º´¿ø ¸¶ÃëÅëÁõÀÇÇаú ¿öÅ©¼¥ : 2022-04-16
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
135 °æ±â Á¦59ȸ ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ¼¼¹Ì³ª : 2018-08-26 0 1,837 2018-07-28
134 ¼­¿ï Á¦8ȸ »ï¼º¼­¿ïº´¿ø ¼Ò¾Æû¼Ò³â¼¾ÅÍ ½ÉÆ÷Áö¾ö(ÁÖÁ¦: ÈçÈ÷ ¸¸³ª°Ô µÇ´Â ¼Ò¾Æû¼Ò³â Áúȯ) : 2018-08-26 0 715 2018-07-28
133 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø Á¦9ȸ ¿¬¼¼ÀÇ´ë ¼Ò¾Æ°úÇб³½Ç, ¼Ò¾Æ¾Ë·¹¸£±âÈ£Èí±âÁúȯ ¿¬¼ö°­Á : 2018-08-26 0 395 2018-07-28
132 ¼­¿ï 2018 ´ëÇѼö¸éÇÐȸ ¿öÅ©¼¥ : 2018-08-26 0 482 2018-07-28
131 °æºÏ ´ëÇѼҾưúÇÐȸ ¼Ò¾Æû¼Ò³â°ú ¿Ü·¡¿¡¼­ Àû¿ë °¡´ÉÇÑ ÀÓ»óÁö½Ä : 2018-08-26 0 652 2018-07-28
130 °æ³² ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ 2018 Post Graduate Asthma School (2ÀÏÂ÷) : 2018-08-26 0 1,080 2018-07-28
129 ¼­¿ï Á¦5ȸ ´ëÇÑ°³¿ø³»°úÀÇ»çȸ °¨¿°º´ ¹× ¹é½Å½ÉÆ÷Áö¿ò : 2018-08-26 0 527 2018-07-28
128 ¼­¿ï Á¦15Â÷ °æ±âµµÀÇ»çȸ Çмú´ëȸ : 2018-08-26 0 1,154 2018-07-28
127 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø °³¿øÀǸ¦ À§ÇÑ °í/½½°üÀý Áúȯ : 2018-08-25 0 565 2018-07-28
126 ºÎ»ê ´ëÇÑÈäºÎ¿Ü°úÇÐȸ 2018 ECMO Symposium and Simulation Workshop : 2018-08-25 0 2,513 2018-07-28
125 ´ëÀü 2018³â ´ëÇÑÅëÁõÇÐȸ Áö¹æ¼øȸ ÃÊÀ½ÆÄ ¹× °æ¸·¿Ü³»½Ã°æWorkshop_ÃÊÀ½ÆÄ¿öÅ©¼ó : 2018-08-25 0 629 2018-07-28
124 ´ëÀü Ãæ³²´ëÇб³º´¿ø Ãæ³²´ëÇб³ ½Å°æ¿Ü°ú ȨĿ¹Ö ½ÉÆ÷Áö¿ò : 2018-08-25 0 902 2018-07-28
123 °æºÏ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Best of ASCO 2018 in Korea : 2018-08-25 0 523 2018-07-28
122 ´ëÀü ´ëÇÑ°»³â±âÇÐȸ 2018 ÇÏ°è¿öÅ©¼¥ : 2018-08-25 0 384 2018-07-28
121 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ¼ö¸éÀÇÇÐ:´ÙÇÐÁ¦ Áø·áÀÇ ÀüÇü : 2018-08-25 0 797 2018-07-28
1401 | 1402 | 1403 | 1404 | 1405 | 1406 | 1407 | 1408 | 1409
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷